Recent studies suggested that genes associated with the pathogenesis of RC, such as vascular endothelial growth factor A (VEGFA), cyclooxygenase 2 (COX2), human antigen R (HUR) and CUG triplet repeat RNA binding protein (CUGBP2), and their products could predict the response to neoadjuvant therapy and, therefore, improve clinical care by selecting an optimal treatment for RC patients, or be prognostic factors in colorectal cancer (CRC) [16,17,18,19,20,21,22,23,24,25,26,27,28,29,30,31,32,33]. This evidence concerns the gene ELAVL1 and colorectal carcinoma.